Kristi Rosa | Authors


TFI and PFS2 in Frontline Advanced Melanoma Improved With Relatlimab/Nivolumab

September 18, 2021

In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.

Lutetium 177 Therapy Success Impacted by Prognostic Risk Group, Receipt of Subsequent Therapies in mCRPC

September 11, 2021

Overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177 may be impacted by Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies.